Yazan Alsayed

5.6k citations

63 papers · 3.3k · h-index 30

Impact in

Hematology top 0.5%
- Multiple Myeloma Research and Treatments
Oncology top 2%
- Peptidase Inhibition and Analysis
- Cytokine Signaling Pathways and Interactions
- Cancer Treatment and Pharmacology

Papers in

Hematology 36
- Multiple Myeloma Research and Treatments 35
Molecular Biology 35
- Protein Degradation and Inhibitors 21
- Cancer therapeutics and mechanisms 5

Co-authors: Bart Barlogie (37 shared papers)John Crowley (28 shared papers)Frits van Rhee (29 shared papers)Elias Anaissie (24 shared papers)Leonidas C. Platanias (11 shared papers)John D. Shaughnessy (27 shared papers)Sarah Waheed (28 shared papers)Bijay Nair (23 shared papers)
Journals: Blood (29 papers)Journal of Clinical Oncology (6 papers)Journal of Biological Chemistry (5 papers)Clinical Cancer Research (4 papers)British Journal of Haematology (3 papers)
Partner nations: United States Canada Japan

In The Last Decade

Yazan Alsayed

60 papers receiving 3.2k citations

Peers

Countries citing papers authored by Yazan Alsayed

Since Specialization

Citations

This map shows the geographic impact of Yazan Alsayed's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yazan Alsayed with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yazan Alsayed more than expected).

Fields of papers citing papers by Yazan Alsayed

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yazan Alsayed. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yazan Alsayed. The network helps show where Yazan Alsayed may publish in the future.

Co-authors

The 25 scholars most cited alongside Yazan Alsayed, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yazan Alsayed Line = papers co-authored together Yazan Alsayed links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 63 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents Haematologica ·Saad Z. Usmani, Christoph Heuck, Alyson E. Mitchell, Jackie Szymonifka, Bijay Nair, Antje Hoering, Yazan Alsayed, Sarah Waheed, Sajjad Haider, Alejandro Restrepo, Frits van Rhee, John Crowley, Bart Barlogie	2012	281
2	Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 British Journal of Haematology ·Bart Barlogie, Elias Anaissie, Frits van Rhee, Jeffrey Haessler, Klaus Hollmig, Mauricio Pineda‐Roman, Michele Cottler‐Fox, Abid Mohiuddin, Yazan Alsayed, Guido Tricot, Vanessa Bolejack, Maurizio Zangari, Joshua Epstein, Nathan Petty, Douglas Steward, Bonnie Jenkins, Jennifer Gurley, Ellen Sullivan, John Crowley, John D. Shaughnessy	2007	258
3	Activation of the p38 Mitogen-activated Protein Kinase by Type I Interferons Journal of Biological Chemistry ·Shahab Uddin, Beata Majchrzak, Joanna Woodson, Pony Arunkumar, Yazan Alsayed, Richard Pine, Peter R. Young, Eleanor N. Fish, Leonidas C. Platanias	1999	210
4	Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities Blood ·Bart Barlogie, Mauricio Pineda‐Roman, Frits van Rhee, Jeff Haessler, Elias Anaissie, Klaus Hollmig, Yazan Alsayed, Sarah Waheed, Nathan Petty, Joshua Epstein, John D. Shaughnessy, Guido Tricot, Maurizio Zangari, Jerome B. Zeldis, Sol Barer, John Crowley	2008	173
5	Superior results of Total Therapy 3 (2003-33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance Blood ·Bijay Nair, Frits van Rhee, John D. Shaughnessy, Elias Anaissie, Jackie Szymonifka, Antje Hoering, Yazan Alsayed, Sarah Waheed, John Crowley, Bart Barlogie	2010	155
6	High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2 Proceedings of the National Academy of Sciences ·Yiming Zhou, Lijuan Chen, Bart Barlogie, Owen Stephens, Xiaosong Wu, (unknown), Marie-Astrid Cartron, Frits van Rhee, Bijay Nair, Sarah Waheed, Mauricio Pineda‐Roman, Yazan Alsayed, Elias Anaissie, John D. Shaughnessy	2010	154
7	Activation of Rac1 and the p38 Mitogen-activated Protein Kinase Pathway in Response to All-trans-retinoic Acid Journal of Biological Chemistry ·Yazan Alsayed, Shahab Uddin, Nadim Mahmud, Fatima Lekmine, Dhananjaya V. Kalvakolanu, Saverio Minucci, Gary Bokoch, Leonidas C. Platanias	2001	146
8	Interferon-α Resistance in a Cutaneous T-Cell Lymphoma Cell Line Is Associated With Lack of STAT1 Expression Blood ·Wenn H. Sun, Carlos Pabon, Yazan Alsayed, Paul P. Huang, Sara Jandeska, Shahab Uddin, Leonidas C. Platanias, Steven T. Rosen	1998	146
9	Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3 Blood ·John D. Shaughnessy, Pingping Qu, Saad Z. Usmani, Christoph Heuck, Qing Zhang, Yiming Zhou, Erming Tian, Ichiro Hanamura, Frits van Rhee, Elias Anaissie, Joshua Epstein, Bijay Nair, Owen Stephens, Ryan Williams, Sarah Waheed, Yazan Alsayed, John Crowley, Bart Barlogie	2011	136
10	High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis Blood ·Frits van Rhee, Vanessa Bolejack, Klaus Hollmig, Mauricio Pineda‐Roman, Elias Anaissie, Joshua Epstein, John D. Shaughnessy, Maurizio Zangari, Guido Tricot, Abid Mohiuddin, Yazan Alsayed, Gail L. Woods, John Crowley, Bart Barlogie	2007	134
11	Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma Cancer ·Bart Barlogie, Elias Anaissie, Jeffrey Haessler, Fritz Van Rhee, Mauricio Pineda‐Roman, Klaus Hollmig, Yazan Alsayed, Joshua Epstein, John D. Shaughnessy, John Crowley	2008	93
12	The Type I Interferon Receptor Mediates Tyrosine Phosphorylation of the CrkL Adaptor Protein Journal of Biological Chemistry ·Sarfraz Ahmad, Yazan Alsayed, Brian Druker, Leonidas C. Platanias	1997	91
13	Engagement of Gab1 and Gab2 in Erythropoietin Signaling Journal of Biological Chemistry ·Amittha Wickrema, Shahab Uddin, Arun K. Sharma, Fei Chen, Yazan Alsayed, Sarfraz Ahmad, Stephen T. Sawyer, Gerald Krystal, Taolin Yi, Keigo Nishada, Masahiko Hibi, Toshio Hirano, Leonidas C. Platanias	1999	91
14	Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy Blood ·Frits van Rhee, Jackie Szymonifka, Elias Anaissie, Bijay Nair, Sarah Waheed, Yazan Alsayed, Nathan Petty, John D. Shaughnessy, Antje Hoering, John Crowley, Bart Barlogie	2010	87
15	Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenström macroglobulinemia Blood ·Anne-Sophie Moreau, Xiaoying Jia, Hai T. Ngo, Xavier Leleu, Garrett O’Sullivan, Yazan Alsayed, Alexey A. Leontovich, Klaus Podar, Jeffrey L. Kutok, John Daley, Suzan Lazo-Kallanian, Evdoxia Hatjiharissi, Marc S. Raab, Lian Xu, Steven P. Treon, Teru Hideshima, Kenneth C. Anderson, Irene M. Ghobrial	2007	80
16	Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease Blood ·Bart Barlogie, Frits van Rhee, John D. Shaughnessy, Joshua Epstein, Shmuel Yaccoby, Mauricio Pineda‐Roman, Klaus Hollmig, Yazan Alsayed, Antje Hoering, Jackie Szymonifka, Elias Anaissie, Nathan Petty, Naveen Sanath Kumar, Geetika Srivastava, Bonnie Jenkins, John Crowley, Jerome B. Zeldis	2008	79
17	Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling Clinical Cancer Research ·Jeffrey Haessler, John D. Shaughnessy, Fenghuang Zhan, John Crowley, Joshua Epstein, Frits van Rhee, Elias Anaissie, Mauricio Pineda‐Roman, Maurizio Zangari, Klaus Hollmig, Abid Mohiuddin, Yazan Alsayed, Antje Hoering, Guido Tricot, Bart Barlogie	2007	78
18	Combination Mammalian Target of Rapamycin Inhibitor Rapamycin and HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Has Synergistic Activity in Multiple Myeloma Clinical Cancer Research ·Lanie Francis, Yazan Alsayed, Xavier Leleu, Xiaoying Jia, Ujjal K. Singha, Judith L. Anderson, Michael Timm, Hai T. Ngo, Ganwei Lu, Alissa Huston, Lori A. Ehrlich, Elizabeth Dimmock, Suzanne Lentzsch, Teru Hideshima, G. David Roodman, Kenneth C. Anderson, Irene M. Ghobrial	2006	78
19	Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? Leukemia ·Saad Z. Usmani, John Crowley, Antje Hoering, Alyson E. Mitchell, Sarah Waheed, Bijay Nair, Yazan Alsayed, Frits Vanrhee, Bart Barlogie	2012	76
20	Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols Blood ·Antje Hoering, John Crowley, John D. Shaughnessy, Klaus Hollmig, Yazan Alsayed, Jackie Szymonifka, Sarah Waheed, Bijay Nair, Frits van Rhee, Elias Anaissie, Bart Barlogie	2009	64

About Yazan Alsayed

Yazan Alsayed is a scholar working on Hematology, Molecular Biology, Oncology, Pathology and Forensic Medicine and Cancer Research, having authored 63 papers that have together received 3.3k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (35 papers), Protein Degradation and Inhibitors (21 papers), Cytokine Signaling Pathways and Interactions (9 papers), Cancer Treatment and Pharmacology (7 papers), Lymphoma Diagnosis and Treatment (6 papers), Cancer therapeutics and mechanisms (5 papers), Cancer Genomics and Diagnostics (4 papers) and Chronic Lymphocytic Leukemia Research (4 papers). The work is most often cited by research in Hematology (2.0k citations), Oncology (1.3k citations), Genetics (307 citations), Molecular Biology (2.0k citations) and Immunology (508 citations). Yazan Alsayed has collaborated with scholars based in United States, Canada and Japan. Frequent co-authors include Bart Barlogie, John Crowley, Frits van Rhee, Elias Anaissie, Leonidas C. Platanias, John D. Shaughnessy, Sarah Waheed, Bijay Nair, Shahab Uddin and Antje Hoering. Their work appears in journals such as Blood, Journal of Clinical Oncology, Journal of Biological Chemistry, Clinical Cancer Research and British Journal of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Yazan Alsayed

Impact in

Papers in i

In The Last Decade

Yazan Alsayed

Peers

Countries citing papers authored by Yazan Alsayed

Fields of papers citing papers by Yazan Alsayed

All Works

About Yazan Alsayed

Explore authors with similar magnitude of impact

Papers in